Document Detail


The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics.
MedLine Citation:
PMID:  12807169     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thromboxane A2 (TXA2), an arachidonate derivative, is a potent bronchoconstrictor; therefore, blocking TXA2 should attenuate airway narrowing. Seratrodast, a TXA2 receptor antagonist, is expected to be a potent antiasthmatic. It was reported that seratrodast reduced bronchial hyperresponsiveness. However, it is controversial whether it reduces airway inflammation. We studied some additional effects of oral seratrodast to inhaled corticosteroids on 10 adult asthmatics in an open-label, crossover design study. Eosinophil cationic protein (ECP) levels in serum and sputum, peak expiratory flow rate (PEF), clinical symptoms, and airway responsiveness were evaluated. Clinical symptom scores were improved by administration of seratrodast (p < 0.05). The addition of seratrodast to asthmatic patients significantly improved mean PEF (p < 0.05). In addition, withdrawal of seratrodast resulted in deterioration of PEF. Airway hyperresponsiveness to acetylcholine measured by Astograph was improved by administration of seratrodast (p < 0.01), and returned to the level of "run-in period" after withdrawal. Administration of seratrodast decreased the concentration of ECP in sputum significantly (p < 0.05), and sputum ECP significantly increased again after withdrawal of (p < 0.05). These results suggest that seratrodast improves clinical symptoms andairway hyperresponsiveness by reducing airway inflammation. Seratrodast may be useful as an anti-inflammatory agent and beneficial when added to inhaled corticosteroids in the treatment of bronchial asthma.
Authors:
Toshihiko Fukuoka; Shuji Miyake; Takeshi Umino; Naohiko Inase; Naoko Tojo; Yasuyuki Yoshizawa
Related Documents :
17402479 - Cold air-induced late-phase bronchoconstriction in horses.
7794289 - A device for overcoming discoordination with metered-dose inhalers.
21247919 - Prognostic significance of different measures of the ventilation-carbon dioxide relatio...
10706489 - Differences in airway responsiveness to acetaldehyde and methacholine in asthma and chr...
18803629 - High frequency jet ventilation through the laryngeal mask airway in a critically obstru...
3595219 - Pulmonary function abnormalities in intentional spray paint inhalation.
15908509 - Kinetics of estimated human muscle capillary blood flow during recovery from exercise.
15694609 - Rehabilitation device with variable resistance and intelligent control.
3759779 - Effect of respiratory alkalosis during exercise on blood lactate.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of asthma : official journal of the Association for the Care of Asthma     Volume:  40     ISSN:  0277-0903     ISO Abbreviation:  J Asthma     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-06-16     Completed Date:  2003-07-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8106454     Medline TA:  J Asthma     Country:  United States    
Other Details:
Languages:  eng     Pagination:  257-64     Citation Subset:  IM    
Affiliation:
The Pulmonary Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Asthmatic Agents / therapeutic use*
Asthma / drug therapy*,  physiopathology
Benzoquinones / therapeutic use*
Blood Proteins / drug effects*
Bronchial Hyperreactivity / drug therapy
Cross-Over Studies
Eosinophil Granule Proteins
Eosinophils / drug effects
Female
Heptanoic Acids / therapeutic use*
Humans
Inflammation Mediators / physiology*
Male
Peak Expiratory Flow Rate
Ribonucleases*
Sputum / chemistry
Thromboxane A2 / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Anti-Asthmatic Agents; 0/Benzoquinones; 0/Blood Proteins; 0/Eosinophil Granule Proteins; 0/Heptanoic Acids; 0/Inflammation Mediators; 112665-43-7/seratrodast; 57576-52-0/Thromboxane A2; EC 3.1.-/Ribonucleases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of rocaltrol on bone mass in patients with pulmonary disease treated with corticosteroids.
Next Document:  Roles of genotypes of beta2-adrenergic receptor in the relationship between eosinophil counts and lu...